APA (7th ed.) Citation

Nie, W., Wang, Z., Zhang, K., Li, B., Cai, Y., Wen, F., . . . Han, B. (2022). ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. BMC Medicine, 20(1), 1. https://doi.org/10.1186/s12916-022-02360-x

Chicago Style (17th ed.) Citation

Nie, Wei, et al. "CtDNA-adjusted BTMB as a Predictive Biomarker for Patients with NSCLC Treated with PD-(L)1 Inhibitors." BMC Medicine 20, no. 1 (2022): 1. https://doi.org/10.1186/s12916-022-02360-x.

MLA (9th ed.) Citation

Nie, Wei, et al. "CtDNA-adjusted BTMB as a Predictive Biomarker for Patients with NSCLC Treated with PD-(L)1 Inhibitors." BMC Medicine, vol. 20, no. 1, 2022, p. 1, https://doi.org/10.1186/s12916-022-02360-x.